You are here
Biosimilars and Branded Insulins
Conference Annotation with Vivian A. Fonseca / ADA 76th Scientific Sessions, New Orleans, June ‘16
Professor Fonseca, Tullis–Tulane Alumni Chair in Diabetes, Tulane University of Medicine, New Orleans, reflects upon biosimilar insulins and branded insulin analogs at the recent 76th scientific session of the American Diabetes Association 2016 in New Orleans, US, June 10-14.
Effects of manufacturing
Biosimilars are biological products that are the reproductions of biopharmaceuticals. A couple of trials presented at the ADA compared biosimilars insulin glargine with insulin analog glargine. Glargine is currently on the market, the biosimilar will become available soon. These insulin analogs are both designed to be as close as possible, but are not totally identical replicas because of the manufacturing process. Safety and efficacy of the biosimilars are comparable to the originators, otherwise the FDA would not approve them. Potentially the biosimilars could be offered at a lower price than the brand name insulin analogs - a benefit for the patients. The long-term effect of the manufacturing process has to be evaluated with regard to antibody formation that might have an impact for individual patients.
As more and more biosimilars will be manufactured, it will be relevant that patients and physicians are aware which particular brand or biosimilar they are using. A switch from one to another might have consequences over time. Overall patients will benefit from a bigger range of products available.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk